Diseases, Conditions, Syndromes

Hallmark of severe COVID-19 patients identified

A large team of researchers with members affiliated with a host of institutions in France has identified what they believe is a hallmark of severe COVID-19 patients. In their paper published in the journal Science, the group ...

Diseases, Conditions, Syndromes

Type III interferon in COVID-19: Protective or harmful?

Our immune system makes interferons and other cytokines to help us fight viruses. But in COVID-19, we've learned that they can also contribute to damaging, potentially life-threatening lung inflammation. New work published ...

Diseases, Conditions, Syndromes

Superinfections pose threat to those being treated for the coronavirus

Viral infections aren't the only cause of deaths during pandemics. A common complication of viral infections such as the flu or the coronavirus is a secondary, superimposed bacterial infection—or a superinfection—resistant ...

Diseases, Conditions, Syndromes

Type III interferons: Protective or harmful in COVID-19?

Interferons and other cytokines produced by the immune system are important defenses against viral infections, but as we have seen in COVID-19, they can also contribute to damaging, potentially life-threatening lung inflammation. ...

Immunology

How a fat cell's immune response makes obesity worse

When obesity occurs, a person's own fat cells can set off a complex inflammatory chain reaction that can further disrupt metabolism and weaken immune response—potentially placing people at higher risk of poor outcomes from ...

Diseases, Conditions, Syndromes

Glucocorticoids are harmful in treating viral respiratory infections

Glucocorticoids are widely used in treating acute respiratory distress syndrome (ARDS) despite there being no indisputable scientific evidence of their effectiveness. The main reason seems to be that there is no effective ...

Medications

Could interferon drugs help fight COVID-19?

(HealthDay)—In the race to find treatments for COVID-19, the antiviral drug remdesivir has gotten much of the attention. But researchers say a class of long-used drugs called interferons also looks promising.

page 8 from 27